Current Theories on the Prevention of Severe Preeclampsia With Low-Molecular Weight Heparin

Hypertension

Volumn 66, Issue 6, 2015, Pages 1098-1103

  McLaughlin, Kelsey ^a,b,d   Drewlo, Sascha ^e   Parker, John D ^a,b   Kingdom, John C P ^a,c,d  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANGIOGENIC PROTEIN; ANTIHYPERTENSIVE AGENT; ASCORBIC ACID; LOW MOLECULAR WEIGHT HEPARIN; MAGNESIUM SULFATE; STEROID; ANTICOAGULANT AGENT;

CARDIOVASCULAR FUNCTION; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; DELIVERY; DISEASE SEVERITY; DRUG MECHANISM; FEMALE; HIGH RISK PATIENT; HUMAN; INCIDENCE; MULTICENTER STUDY (TOPIC); NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PHARMACEUTICAL CARE; PLACENTA; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL GROWTH; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SPONTANEOUS ABORTION; VASCULAR DISEASE; BLOOD PRESSURE; DRUG EFFECTS; PATHOPHYSIOLOGY; PRE-ECLAMPSIA; SEVERITY OF ILLNESS INDEX; VASCULAR ENDOTHELIUM;

ANTICOAGULANTS; BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PRE-ECLAMPSIA; PREGNANCY; SEVERITY OF ILLNESS INDEX;

EID: 84947491799     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.05770     Document Type: Review

References (76)

1. Abbas AE, Lester SJ, Connolly H. Pregnancy and the cardiovascular system. Int J Cardiol. 2005;98:179-189. doi: 10.1016/j.ijcard.2003.10.028.
2. Easterling TR, Benedetti TJ, Schmucker BC, Millard SP. Maternal hemodynamics in normal and preeclamptic pregnancies: a longitudinal study. Obstet Gynecol. 1990;76:1061-1069.
3. Siu SC, Colman JM. Heart disease and pregnancy. Heart. 2001;85:710-715.
4. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33:130-137. doi: 10.1053/j.semperi.2009.02.010.
5. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstetrics and gynecology. 2013;122:1122-1131. doi: 10.1097/01.AOG.0000437382.03963.88.
6. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308:1592-1594. doi: 10.1126/science.1111726.
7. Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation. 2011;123:2856-2869. doi: 10.1161/CIRCULATIONAHA.109.853127.
8. Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation. 2010;122:478-487. doi: 10.1161/CIRCULATIONAHA.109.895458.
9. Yinon Y, Kingdom JC, Odutayo A, Moineddin R, Drewlo S, Lai V, Cherney DZ, Hladunewich MA. Vascular dysfunction in women with a history of preeclampsia and intrauterine growth restriction: insights into future vascular risk. Circulation. 2010;122:1846-1853. doi: 10.1161/CIRCULATIONAHA.110.948455.
10. Melchiorre K, Sutherland GR, Liberati M, Thilaganathan B. Preeclampsia is associated with persistent postpartum cardiovascular impairment. Hypertension. 2011;58:709-715. doi: 10.1161/HYPERTENSIONAHA.111.176537.
11. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet. 2005;366:1797-1803. doi: 10.1016/S0140-6736(05)67726-4.
12. Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ. 2001;323:1213-1217.
13. Staff AC, Benton SJ, von Dadelszen P, Roberts JM, Taylor RN, Powers RW, Charnock-Jones DS, Redman CW. Redefining preeclampsia using placenta-derived biomarkers. Hypertension. 2013;61:932-942. doi: 10.1161/HYPERTENSIONAHA.111.00250.
14. North RA, McCowan LM, Dekker GA, Poston L, Chan EH, Stewart AW, Black MA, Taylor RS, Walker JJ, Baker PN, Kenny LC. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ. 2011;342:d1875.
15. Poon LC, Nicolaides KH. Early prediction of preeclampsia. Obstet Gynecol Int. 2014;2014:297397. doi: 10.1155/2014/297397.
16. Audibert F, Boucoiran I, An N, Aleksandrov N, Delvin E, Bujold E, Rey E. Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women. Am J Obstet Gynecol. 2010;203:383.e1-383.e8. doi: 10.1016/j.ajog.2010.06.014.
17. Yu CK, Smith GC, Papageorghiou AT, Cacho AM, Nicolaides KH; Fetal Medicine Foundation Second Trimester Screening Group. An integrated model for the prediction of preeclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. Am J Obstet Gynecol. 2005;193:429-436. doi: 10.1016/j.ajog.2004.12.014.
18. Kenny LC, Black MA, Poston L, Taylor R, Myers JE, Baker PN, McCowan LM, Simpson NA, Dekker GA, Roberts CT, Rodems K, Noland B, Raymundo M, Walker JJ, North RA. Early pregnancy prediction of preeclampsia in nulliparous women, combining clinical risk and biomarkers: the Screening for Pregnancy Endpoints (SCOPE) international cohort study. Hypertension. 2014;64:644-652. doi: 10.1161/HYPERTENSIONAHA.114.03578.
19. Fenton C, Hobson SR, Wallace EM, Lim R. Future therapies for pre-eclampsia: beyond treading water. Aust N Z J Obstet Gynaecol. 2014;54:3-8. doi: 10.1111/ajo.12134.
20. Sibai BM, Barton JR. Expectant management of severe preeclampsia remote from term: patient selection, treatment, and delivery indications. Am J Obstet Gynecol. 2007;196:514.e1-514.e9. doi: 10.1016/j. ajog.2007.02.021.
21. Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH; Vitamins in Pre-eclampsia (VIP) Trial Consortium. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet. 2006;367:1145-1154. doi: 10.1016/S0140-6736(06)68433-X.
22. Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L, Torloni MR. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2014;6:CD001059. doi: 10.1002/14651858.CD001059.pub4.
23. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA; PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007;369:1791-1798. doi: 10.1016/S0140-6736(07)60712-0.
24. LeFevre ML; U.S. Preventive Services Task Force. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161:819-826. doi: 10.7326/M14-1884.
25. Bartsch E, Park AL, Kingdom JC, Ray JG. Risk threshold for starting low dose aspirin in pregnancy to prevent preeclampsia: an opportunity at a low cost. PLoS One. 2015;10:e0116296. doi: 10.1371/journal.pone.0116296.
26. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest JC, Giguère Y. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a metaanalysis. Obstet Gynecol. 2010;116(2 Pt 1):402-414. doi: 10.1097/AOG.0b013e3181e9322a.
27. Henderson JT, Whitlock EP, O'Connor E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2014;160:695-703. doi: 10.7326/M13-2844.
28. Thadhani R, Kisner T, Hagmann H, et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation. 2011;124:940-950. doi: 10.1161/CIRCULATIONAHA.111.034793.
29. Rey E, Garneau P, David M, Gauthier R, Leduc L, Michon N, Morin F, Demers C, Kahn SR, Magee LA, Rodger M. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost. 2009;7:58-64. doi: 10.1111/j.1538-7836.2008.03230.x.
30. Gris JC, Chauleur C, Faillie JL, Baer G, Marès P, Fabbro-Peray P, Quéré I, Lefrant JY, Haddad B, Dauzat M. Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. The pilot randomised controlled NOH-AP trial. Thromb Haemost. 2010;104:771-779. doi: 10.1160/TH10-03-0167.
31. Gris JC, Chauleur C, Molinari N, Marès P, Fabbro-Peray P, Quéré I, Lefrant JY, Haddad B, Dauzat M. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial. Thromb Haemost. 2011;106:1053-1061. doi: 10.1160/TH11-05-0340.
32. Martinelli I, Ruggenenti P, Cetin I, et al; HAPPY Study Group. Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood. 2012;119:3269-3275. doi: 10.1182/blood-2011-11-391383.
33. Sergio F, Maria Clara D, Gabriella F, Giorgia S, Sara De Carolis, Giancarlo P, Alessandro C. Prophylaxis of recurrent preeclampsia: low-molecular-weight heparin plus low-dose aspirin versus lowdose aspirin alone. Hypertens Pregnancy. 2006;25:115-127. doi: 10.1080/10641950600745517.
34. North RA, Ferrier C, Gamble G, Fairley KF, Kincaid-Smith P. Prevention of preeclampsia with heparin and antiplatelet drugs in women with renal disease. Aust N Z J Obstet Gynaecol. 1995;35:357-362.
35. Kupferminc M, Rimon E, Many A, Maslovitz S, Lessing JB, Gamzu R. Low molecular weight heparin versus no treatment in women with previous severe pregnancy complications and placental findings without thrombophilia. Blood Coagul Fibrinolysis. 2011;22:123-126. doi: 10.1097/MBC.0b013e328343315c.
36. Mello G, Parretti E, Fatini C, Riviello C, Gensini F, Marchionni M, Scarselli GF, Gensini GF, Abbate R. Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension. 2005;45:86-91. doi: 10.1161/01.HYP.0000149950.05182. a3.
37. de Vries JI, van Pampus MG, Hague WM, Bezemer PD, Joosten JH; FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. J Thromb Haemost. 2012;10:64-72. doi: 10.1111/j.1538-7836.2011.04553.x.
38. Dodd JM, McLeod A, Windrim RC, Kingdom J. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database Syst Rev. 2013;7:CD006780. doi: 10.1002/14651858.CD006780.pub3.
39. Rodger MA, Carrier M, Le Gal G, Martinelli I, Perna A, Rey E, de Vries JI, Gris JC; Low-Molecular-Weight Heparin for Placenta-Mediated Pregnancy Complications Study Group. Meta-analysis of low-molecularweight heparin to prevent recurrent placenta-mediated pregnancy complications. Blood. 2014;123:822-828. doi: 10.1182/blood-2013-01-478958.
40. Clark P, Walker ID, Langhorne P, Crichton L, Thomson A, Greaves M, Whyte S, Greer IA; Scottish Pregnancy Intervention Study (SPIN) Collaborators. SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood. 2010;115:4162-4167. doi: 10.1182/blood-2010-01-267252.
41. Laskin CA, Spitzer KA, Clark CA, Crowther MR, Ginsberg JS, Hawker GA, Kingdom JC, Barrett J, Gent M. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol. 2009;36:279-287. doi: 10.3899/jrheum.080763).
42. Pasquier E, de Saint Martin L, Bohec C, Chauleur C, Bretelle F, Marhic G, Le Gal G, Debarge V, Lecomte F, Denoual-Ziad C, Lejeune-Saada V, Douvier S, Heisert M, Mottier D. Enoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial. Blood. 2015;125:2200-2205. doi: 10.1182/blood-2014-11-610857.
43. Kaandorp SP, Goddijn M, van der Post JA, Hutten BA, Verhoeve HR, Hamulyák K, Mol BW, Folkeringa N, Nahuis M, Papatsonis DN, Büller HR, van der Veen F, Middeldorp S. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med. 2010;362:1586-1596. doi: 10.1056/NEJMoa1000641.
44. Rodger MA, Hague WM, Kingdom J, et al; TIPPS Investigators. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet. 2014;384:1673-1683. doi: 10.1016/S0140-6736(14)60793-5.
45. Kingdom JC, Walker M, Proctor LK, Keating S, Shah PS, McLeod A, Keunen J, Windrim RC, Dodd JM. Unfractionated heparin for second trimester placental insufficiency: a pilot randomized trial. J Thromb Haemost. 2011;9:1483-1492. doi: 10.1111/j.1538-7836.2011.04407.x.
46. D'Souza R, Keating S, Walker M, Drewlo S, Kingdom J. Unfractionated heparin and placental pathology in high-risk pregnancies: secondary analysis of a pilot randomized controlled trial. Placenta. 2014;35:816-823. doi: 10.1016/j.placenta.2014.07.010.
47. Qiu C, Williams MA, Leisenring WM, Sorensen TK, Frederick IO, Dempsey JC, Luthy DA. Family history of hypertension and type 2 diabetes in relation to preeclampsia risk. Hypertension. 2003;41:408-413. doi: 10.1161/01.HYP.0000056996.25503.F5.
48. Rigó J Jr, Boze T, Derzsy Z, Derzbach L, Treszl A, Lázár L, Sobel G, Vásárhelyi B. Family history of early-onset cardiovascular disorders is associated with a higher risk of severe preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2006;128:148-151. doi: 10.1016/j.ejogrb.2006.02.019.
49. Savvidou MD, Hingorani AD, Tsikas D, Frölich JC, Vallance P, Nicolaides KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet. 2003;361:1511-1517. doi: 10.1016/S0140-6736(03)13177-7.
50. Savvidou MD, Noori M, Anderson JM, Hingorani AD, Nicolaides KH. Maternal endothelial function and serum concentrations of placental growth factor and soluble endoglin in women with abnormal placentation. Ultrasound Obstet Gynecol. 2008;32:871-876. doi: 10.1002/uog.6126.
51. Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res. 2004;95:884-891. doi: 10.1161/01.RES.0000147365.86159.f5.
52. Searle J, Mockel M, Gwosc S, et al. Heparin strongly induces soluble fms-like tyrosine kinase 1 release in vivo and in vitro-brief report. Arterioscler Thromb Vasc Biol. 2011;31:2972-2974. doi: 10.1161/ATVBAHA.111.237784.
53. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649-658. doi: 10.1172/JCI17189.
54. Gilbert JS, Babcock SA, Granger JP. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fmslike tyrosine kinase-1 expression. Hypertension. 2007;50:1142-1147. doi: 10.1161/HYPERTENSIONAHA.107.096594.
55. Bergmann A, Ahmad S, Cudmore M, Gruber AD, Wittschen P, Lindenmaier W, Christofori G, Gross V, Gonzalves ACh, Gröne HJ, Ahmed A, Weich HA. Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J Cell Mol Med. 2010;14(6B):1857-1867. doi: 10.1111/j.1582-4934.2009.00820.x.
56. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672-683. doi: 10.1056/NEJMoa031884.
57. Doherty A, Carvalho JC, Drewlo S, El-Khuffash A, Downey K, Dodds M, Kingdom J. Altered hemodynamics and hyperuricemia accompany an elevated sFlt-1/PlGF ratio before the onset of early severe preeclampsia. J Obstet Gynaecol Can. 2014;36:692-700.
58. Baldus S, Rudolph V, Roiss M, et al. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation. 2006;113:1871-1878. doi: 10.1161/CIRCULATIONAHA.105.590083.
59. Gandley RE, Rohland J, Zhou Y, Shibata E, Harger GF, Rajakumar A, Kagan VE, Markovic N, Hubel CA. Increased myeloperoxidase in the placenta and circulation of women with preeclampsia. Hypertension. 2008;52:387-393. doi: 10.1161/HYPERTENSIONAHA.107.107532.
60. Rudolph TK, Rudolph V, Witte A, Klinke A, Szoecs K, Lau D, Heitzer T, Meinertz T, Baldus S. Liberation of vessel adherent myeloperoxidase by enoxaparin improves endothelial function. Int J Cardiol. 2010;140:42-47. doi: 10.1016/j.ijcard.2008.10.035.
61. Tasatargil A, Ogutman C, Golbasi I, Karasu E, Dalaklioglu S. Comparison of the vasodilatory effect of nadroparin, enoxaparin, dalteparin, and unfractioned heparin in human internal mammary artery. J Cardiovasc Pharmacol. 2005;45:550-554.
62. Georgescu A, Popov D, Capraru M, Simionescu M. Enoxaparin-a low molecular weight heparin, restores the altered vascular reactivity of resistance arteries in aged and aged-diabetic hamsters. Vascul Pharmacol. 2003;40:167-174.
63. Georgescu A, Alexandru N, Nemecz M, Titorencu I, Popov D. Enoxaparin reduces adrenergic contraction of resistance arterioles in aging and in aging associated with diabetes via engagement of MAP kinase pathway. Blood Coagul Fibrinolysis. 2011;22:310-316. doi: 10.1097/MBC.0b013e328345123d.
64. Yokokawa K, Tahara H, Kohno M, Mandal AK, Yanagisawa M, Takeda T. Heparin regulates endothelin production through endothelium-derived nitric oxide in human endothelial cells. J Clin Invest. 1993;92:2080-2085. doi: 10.1172/JCI116805.
65. Li Y, Wu Y, Gong X, Shi X, Qiao F, Liu H. Low molecular weight heparin decreases the permeability of glomerular endothelial cells when exposed to pre-eclampsia serum in vitro. Nephrology (Carlton). 2012;17:754-759. doi: 10.1111/j.1440-1797.2012.01657.x.
66. Liu W, Qiao F, Liu H, Gong X, Shi X, Li Y, Wu Y. Low molecular weight heparin improves proteinuria in rats with L-NAME induced preeclampsia by decreasing the expression of nephrin, but not podocin. Hypertens Pregnancy. 2015;34:24-35. doi: 10.3109/10641955.2014.951655.
67. Zhang Y, Liu F, Chen S, Zhong M. Low-molecular-weight heparin protects kidney through an anti-apoptotic mechanism in a rat pre-eclamptic model. Eur J Obstet Gynecol Reprod Biol. 2015;188:51-55. doi: 10.1016/j.ejogrb.2015.02.001.
68. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol. 1999;180(2 Pt 1):499-506.
69. Sacks GP, Studena K, Sargent K, Redman CW. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol. 1998;179:80-86.
70. Penning M, Chua JS, van Kooten C, Zandbergen M, Buurma A, Schutte J, Bruijn JA, Khankin EV, Bloemenkamp K, Karumanchi SA, Baelde H. Classical complement pathway activation in the kidneys of women with preeclampsia. Hypertension. 2015;66:117-125. doi: 10.1161/HYPERTENSIONAHA.115.05484.
71. Oberkersch R, Attorresi AI, Calabrese GC. Low-molecular-weight heparin inhibition in classical complement activation pathway during pregnancy. Thromb Res. 2010;125:e240-e245. doi: 10.1016/j. thromres.2009.11.030.
72. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004;10:1222-1226. doi: 10.1038/nm1121.
73. Hagmann H, Bossung V, Belaidi AA, Fridman A, Karumanchi SA, Thadhani R, Schermer B, Mallmann P, Schwarz G, Benzing T, Brinkkoetter PT. Low-molecular weight heparin increases circulating sFlt-1 levels and enhances urinary elimination. PLoS One. 2014;9:e85258. doi: 10.1371/journal.pone.0085258.
74. Sela S, Natanson-Yaron S, Zcharia E, Vlodavsky I, Yagel S, Keshet E. Local retention versus systemic release of soluble VEGF receptor-1 are mediated by heparin-binding and regulated by heparanase. Circ Res. 2011;108:1063-1070. doi: 10.1161/CIRCRESAHA.110.239665.
75. Yinon Y, Siu SC, Warshafsky C, Maxwell C, McLeod A, Colman JM, Sermer M, Silversides CK. Use of low molecular weight heparin in pregnant women with mechanical heart valves. Am J Cardiol. 2009;104:1259-1263. doi: 10.1016/j.amjcard.2009.06.040.
76. Sandrim VC, Palei AC, Metzger IF, Gomes VA, Cavalli RC, Tanus-Santos JE. Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble fms-like tyrosine kinase-1 and soluble endogline in preeclampsia. Hypertension. 2008;52:402-407. doi: 10.1161/HYPERTENSIONAHA.108.115006.